These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3991532)

  • 1. The bone scan in patients with aluminium-associated bone disease.
    Botella J; Gallego JL; Fernandez-Fernandez J; Sanz-Guajardo D; de Miguel A; Ramos J; Franco P; Enriques R; Sanz-Moreno C
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():403-9. PubMed ID: 3991532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 4. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dialysis osteomalacia: clinical aspects and physiopathological mechanisms.
    Drüeke T; Cournot-Witmer G
    Clin Nephrol; 1985; 24 Suppl 1():S26-9. PubMed ID: 3915957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA; McParland C; Keogh JA
    Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.
    Barré PE; Prichard S
    Int J Artif Organs; 1986 May; 9(3):167-72. PubMed ID: 3733242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 14. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 15. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
    ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

  • 17. Healing of fracturing-bone disease occurring in patients on dialysis. A prospective study.
    Milne FJ; Hudson GA; Meyers AM; Baily P; Barmeir E; Dubowitz B; Reis P
    S Afr Med J; 1982 Jun; 61(25):955-9. PubMed ID: 7089762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential diagnosis between secondary hyperparathyroidism and aluminum intoxication in uremic patients: usefulness of 99mTc-pyrophosphate bone scintigraphy.
    Kinnaert P; Van Hooff I; Schoutens A; Bergmann P; Fuss M; Dratwa M; Vienne A; Pasteels JL; van Geertruyden J; Vanherweghem JL
    World J Surg; 1989; 13(2):219-23; discussion 223-4. PubMed ID: 2543146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detecting and evaluating hyperaluminemia in 3 dialysis centers].
    Balabán D; Simícková J; Kubátko J; Syrovátka P
    Cas Lek Cesk; 1989 Dec; 128(51):1611-4. PubMed ID: 2631999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report 288: osteomalacia and secondary hyperparathyroidism (dialysis-induced), with aluminum deposition.
    Llewellyn CH; Resnik CS; Brower AC
    Skeletal Radiol; 1984; 12(3):223-6. PubMed ID: 6494942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.